265 related articles for article (PubMed ID: 26091536)
1. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
Paoloni M; Mazcko C; Selting K; Lana S; Barber L; Phillips J; Skorupski K; Vail D; Wilson H; Biller B; Avery A; Kiupel M; LeBlanc A; Bernhardt A; Brunkhorst B; Tighe R; Khanna C
PLoS One; 2015; 10(6):e0129954. PubMed ID: 26091536
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.
Strauss J; Heery CR; Kim JW; Jochems C; Donahue RN; Montgomery AS; McMahon S; Lamping E; Marté JL; Madan RA; Bilusic M; Silver MR; Bertotti E; Schlom J; Gulley JL
Clin Cancer Res; 2019 Jan; 25(1):99-109. PubMed ID: 30131389
[TBL] [Abstract][Full Text] [Related]
3. The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Fallon J; Tighe R; Kradjian G; Guzman W; Bernhardt A; Neuteboom B; Lan Y; Sabzevari H; Schlom J; Greiner JW
Oncotarget; 2014 Apr; 5(7):1869-84. PubMed ID: 24681847
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes.
van Herpen CM; Looman M; Zonneveld M; Scharenborg N; de Wilde PC; van de Locht L; Merkx MA; Adema GJ; de Mulder PH
Clin Cancer Res; 2004 Apr; 10(8):2626-35. PubMed ID: 15102664
[TBL] [Abstract][Full Text] [Related]
5. Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12.
Toney NJ; Gatti-Mays ME; Tschernia NP; Strauss J; Gulley JL; Schlom J; Donahue RN
Int Immunopharmacol; 2023 Mar; 116():. PubMed ID: 37234190
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
10. A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.
Gatti-Mays ME; Tschernia NP; Strauss J; Madan RA; Karzai FH; Bilusic M; Redman J; Sater HA; Floudas CS; Toney NJ; Donahue RN; Jochems C; Marté JL; Francis D; McMahon S; Lamping E; Cordes L; Schlom J; Gulley JL
Oncologist; 2023 Apr; 28(4):364-e217. PubMed ID: 36640137
[TBL] [Abstract][Full Text] [Related]
11. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
Fallon JK; Vandeveer AJ; Schlom J; Greiner JW
Oncotarget; 2017 Mar; 8(13):20558-20571. PubMed ID: 28423552
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
[TBL] [Abstract][Full Text] [Related]
14. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
15. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.
Morillon YM; Su Z; Schlom J; Greiner JW
J Immunother Cancer; 2019 Jun; 7(1):150. PubMed ID: 31186063
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine.
Minnar CM; Lui G; Gulley JL; Schlom J; Gameiro SR
Front Oncol; 2023; 13():1321318. PubMed ID: 38260854
[TBL] [Abstract][Full Text] [Related]
17. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.
Zhang L; Morgan RA; Beane JD; Zheng Z; Dudley ME; Kassim SH; Nahvi AV; Ngo LT; Sherry RM; Phan GQ; Hughes MS; Kammula US; Feldman SA; Toomey MA; Kerkar SP; Restifo NP; Yang JC; Rosenberg SA
Clin Cancer Res; 2015 May; 21(10):2278-88. PubMed ID: 25695689
[TBL] [Abstract][Full Text] [Related]
20. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
Magee K; Marsh IR; Turek MM; Grudzinski J; Aluicio-Sarduy E; Engle JW; Kurzman ID; Zuleger CL; Oseid EA; Jaskowiak C; Albertini MR; Esbona K; Bednarz B; Sondel PM; Weichert JP; Morris ZS; Hernandez R; Vail DM
PLoS One; 2021; 16(8):e0255798. PubMed ID: 34383787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]